Endocrinology, Vol 109, 2255-2257, Copyright © 1981 by Endocrine Society

ARTICLES

Somatostatin in rat tissues is depleted by cysteamine administration

S Szabo and S Reichlin

Administration of cysteamine (mercaptoethylamine) induces in rats severe perforating duodenal ulcers. Because the ulcerogenic properties of cysteamine are markedly reduced by treatment with somatostatin, we considered the possibility that cysteamine-induced duodenal ulcer might be mediated by depletion of tissue somatostatin, and thereby of its paracrine influences on gastrin and gastric acid secretion. To test this hypothesis, we measured the concentration of immunoreactive somatostatin (IR-somatostatin) in stomach and duodenal mucosa at intervals after administration of a single ulcerogenic dose (30 mg/kg by stomach tube). IR-somatostatin in these tissues fell rapidly to reach a minimum at 4 h (stomach 31%, duodenum 60% of control respectively). IR-somatostatin in hypothalamus and pancreas decreased gradually to a minimum at 7 h. Another duodenal ulcerogen, propionitrile (10 mg/100 g bw, s.c.) which is more toxic than cysteamine, and several stressful procedures including ether anesthesia, restraint and s.c. formalin did not lower stomach or duodenal IR-somatostatin. Gut, pancreas and hypothalamic VIP levels were not influenced by cysteamine. These findings suggest that cysteamine is a relatively specific depletor of tissue somatostatin. Because blood levels of somatostatin fell, and only trivial amounts of the peptide were found in the stomach lumen after cysteamine administration, it appears likely that this agent acts at the cellular level to cause breakdown of preformed somatostatin and/or to acutely reduce its synthesis.

This article has been cited by other articles:

				C. Kluge, C. Stoppel, C. Szinyei, O. Stork, and H.-C. Pape Role of the somatostatin system in contextual fear memory and hippocampal synaptic plasticity Learn. Mem., April 3, 2008; 15(4): 252 - 260. [Abstract] [Full Text] [PDF]

				Q. Yang, G. Lian, and X. Gong Enhancement of Mucosal Immune Responses in Chickens by Oral Administration of Cysteamine Poult. Sci., July 1, 2007; 86(7): 1323 - 1328. [Abstract] [Full Text] [PDF]

				C. M. Yang, A. G. Chen, Q. H. Hong, J. X. Liu, and J. S. Liu Effects of cysteamine on growth performance, digestive enzyme activities, and metabolic hormones in broilers. Poult. Sci., November 1, 2006; 85(11): 1912 - 1916. [Abstract] [Full Text] [PDF]

				S. Fukuhara, H. Suzuki, T. Masaoka, M. Arakawa, H. Hosoda, Y. Minegishi, K. Kangawa, H. Ishii, M. Kitajima, and T. Hibi Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers Am J Physiol Gastrointest Liver Physiol, July 1, 2005; 289(1): G138 - G145. [Abstract] [Full Text] [PDF]

				N. Iijima, Y. Matsumoto, T. Yano, M. Tanaka, T. Yamamoto, K. Kakihara, Y. Kataoka, Y. Tamada, H. Matsumoto, N. Suzuki, et al. A Novel Function of Prolactin-Releasing Peptide in the Control of Growth Hormone via Secretion of Somatostatin from the Hypothalamus Endocrinology, July 1, 2001; 142(7): 3239 - 3243. [Abstract] [Full Text] [PDF]

				W. Millard, S. Sagar, D. Landis, and J. Martin Cysteamine: a potent and specific depletor of pituitary prolactin Science, July 30, 1982; 217(4558): 452 - 454. [Abstract] [PDF]